In several recent aspirin-controlled trials P2Y12 blocker monotherapy halved the bleeding risk when aspirin was discontinued at the time of DAPT cessation and did not seem to increase the number of ischaemic events such as myocardial infarction or stent thrombosis. This evidence concerns the gene P2RY12 and myocardial infarction.